In this article, we will be taking a look at the 5 fastest growing biotech companies in the US. If you wish to learn about the global biotech landscape, head straight to the 20 Fastest Growing Biotech Companies In The US.
5. United Therapuetics Corporation (NASDAQ:UTHR)
Year on Year growth: 20.20%
United Therapeutics Corporation, a leading US biotech company, reported $614.7 million in revenue and $217.1 million in net income for Q4 and full year 2023. They’re engaged in litigation with the FDA over rival Liquidia’s drug application. United Therapeutics alleges FDA bypassed rules for Liquidia’s application. The company recently initiated Phase 3 TETON PPF study for nebulized Tyvaso and was recognized by Newsweek as a top responsible company in 2024. United Therapeutics focuses on advancing medical research, developing novel therapies, and expanding organ availability. Their commitment to innovation positions them as a key player in biotech.
4. Amyris, Inc.
Year on Year growth: 20.46%
Amyris, Inc. is a leading US biotech company renowned for its innovative use of synthetic biology to create sustainable ingredients. It converts plant sugars into rare bioidentical molecules, promoting environmentally friendly products. Amyris has launched clean consumer brands and developed 13 sustainable ingredients used globally. Recent trends include
- focusing on clean chemistry,
- expanding its portfolio of sustainable brands and
- pioneering synthetic biology for products like RNA vaccines and sweeteners.
Despite bankruptcy filing in August 2023, Amyris aims to maintain quality and sustainability while expanding its product range.
3. CSL Limited
Year on Year growth: 21.14%
CSL Limited, standing third among the fastest growing biotech companies in the US, comprises CSL Behring, CSL Seqirus, and CSL Vifor, specializing in rare diseases, influenza vaccines, and nephrology. CSL Behring leads in treating rare diseases, while CSL Seqirus focuses on influenza prevention, and CSL Vifor addresses iron deficiency and nephrology.
Recent trends include active participation in medical events, patient advisory boards to improve clinical trials, and acquisitions like Vitaeris and Vifor Pharma AG. Financially, CSL reported a revenue of US$12.7 billion in 2023. Future trends indicate growth prospects in influenza vaccines and iron deficiency treatments, supported by CSL’s focus on rare diseases and innovative therapies.
2. Twist Bioscience Corporation (NASDAQ:TWST)
Year on Year growth: 21.58%
Twist Bioscience Corporation (NASDAQ:TWST), a top biotech company, pioneers DNA synthesis through a silicon chip platform. It revolutionizes drug discovery with automated precision synthesis, offering a wide range of DNA products. Collaborations like Genome Project-Write and Astellas highlight its commitment to innovation. Twist Bioscience Corporation (NASDAQ:TWST)’s upcoming trends include expanding into antibody production, NGS sequencing, and utilizing DNA for diverse high-value products across industries.
1. Novo Nordisk A/S (NYSE:NVO)
Year on Year growth: 31.26%
Novo Nordisk A/S (NYSE:NVO), standing first among the fastest growing biotech companies in the US, leads in diabetes, obesity, hemophilia, and rare endocrine disorders treatments. It prioritizes innovative medicine development, emphasizing sustainability and societal value. Noteworthy achievements include using 100% renewable power in production and investing billions in expansion. Recent acquisitions and investments signify growth strategies. Novo Nordisk A/S (NYSE:NVO) upcoming priorities include tackling type 2 diabetes and obesity prevention while ensuring global access to care.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also take a peek at 16 Best Exercises For Lower Back Pain and the World’s 20 Most Expensive Countries To Live In 2024.
